AU · rank #20 · 2026-10-23
GRAL
NASDAQ · $5.47B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 0.640 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.69 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $0 across 0 unique buyers. | -0.207 |
| Analyst upside Consensus target $131.30 | +3.3% |
| Momentum acceleration 3-month minus 12-month momentum. | +73.86% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 3.91 |
| Gross margin TTM | +49.7% |
| 52w high | $166.48 |
| Market cap (USD) | $5.47B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
GRAIL, LLC is a healthcare diagnostics company developing and commercializing Galleri, a methylation-based blood test designed to detect early-stage signals across more than 50 cancer types.
Rationale
The analyst upside signal is supported by 7 price target raises in 30 days and 100% revision agreement following a favorable FDA advisory committee vote and a 44.9% earnings surprise.
Material risks
- 1The FDA could delay or decline final PMA approval, or require further longitudinal data showing Galleri improves overall survival rather than early signal detection.
- 2High operational burn and negative gross margins ($110.2 million net loss and $12.6 million gross loss in Q2) could force equity dilution before reaching broad insurance reimbursement.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 1 of 3 voted to proceed.